Evaluating saliva markers in patients with different periodontal diseases
Assessment of Saliva Adseverin,1-Alpha Defensin and sRANKL (Soluble RANKL) Levels In Individuals With Different Periodontal Diseases
This study is testing if certain saliva markers can help us understand the different types of gum diseases in healthy non-smokers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 20 Years to 60 Years |
| Sex | All |
| Sponsor | Izmir Katip Celebi University Academic / other |
| Locations | 1 site (İzmir, Çiğli) |
| Trial ID | NCT06402877 on ClinicalTrials.gov |
What this trial studies
This study aims to detect levels of Adseverin, 1-alpha Defensin, and sRANKL in saliva samples from individuals with varying periodontal health, including those with periodontitis, gingivitis, and healthy gums. A total of 60 systemically healthy non-smokers will participate, providing saliva samples and undergoing full-mouth clinical periodontal assessments. The study will utilize enzyme-linked immunosorbent assay (ELISA) to analyze the correlation between these salivary markers and clinical parameters of periodontal diseases.
Who should consider this trial
Good fit: Ideal candidates include systemically healthy non-smokers with either periodontitis, gingivitis, or healthy periodontal status.
Not a fit: Patients with systemic health issues, smokers, or those on continuous medication may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of periodontal disease mechanisms and improve diagnostic methods.
How similar studies have performed: While similar studies have explored salivary biomarkers in periodontal diseases, this specific combination of markers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Systemically healthy (The determination of healthy volunteers will be based on the statements of the patients in the anamnesis. No additional examinations will be made.) At least twenty permanent teeth in the mouth Non-smoker No medication for continuous use Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months. Not in pregnancy or lactation period. For the periodontitis group that has not received periodontal treatment in the last 6 months For the periodontitis group; According to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss For the gingivitis group; According to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss For healthy group; According to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study. Exclusion Criteria: Any oral or systemic disease Regularly using a systemic medication During pregnancy or lactation Received periodontal treatment within the last 6 months. Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months Smokers are not included in the study
Where this trial is running
İzmir, Çiğli
- Izmir Katip Çelebi University Department of Periodontology — İzmir, Çiğli, Turkey (Recruiting)
Study contacts
- Study coordinator: Ayşe Efe
- Email: efeayse421@gmail.com
- Phone: +905076372147
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.